-
MorphoSys started from scratch to build Ylanthia, a new antibody library that the company will launch this year to replace its aging HuCAL platform.
Published on 1/30/2012
-
A Phase III trial of Biocon's anti-CD6 mAb itolizumab showed lower efficacy than other biologics in psoriasis, but the biotech hopes lower infection rates will differentiate it from the anti-TNFs.
Published on 1/23/2012
-
Servier is optioning an anti-B7-H3 mAb from MacroGenics to add a multi-pronged mechanism that could be an improvement on immunomodulatory mAbs that target other B7 family proteins, such as Yervoy from BMS.
Published on 1/2/2012
-
Doctors say the latest Phase III data for pertuzumab support use in first-line metastatic breast cancer, but they are more excited about upcoming data in early stage disease.
Published on 12/19/2011
-
Oxyrane hopes its enzyme replacement therapy for Pompe's can beat Genzyme's Myozyme by reducing dosage and infusion times and lowering cost to patients and payers.
Published on 12/12/2011
-
Roche has done another deal with PTC Therapeutics, this time for a small molecule program in preclinical development for spinal muscular atrophy.
Published on 12/12/2011
-
A year after starting a biomarker study in rheumatoid arthritis, a broad-based consortium has retooled its recruitment strategy and now hopes to report results in 2013.
Published on 12/5/2011
-
Combo conundrums Combo cancer pipeline At least eight of the major pharma companies have deals with another pharma to combine two investigational or recently approved agents in clinical trials for cancer. …
Published on 11/21/2011
-
A first look at Lilly's evacetrapib shows it is competitive with other CETP inhibitors. But the real measure of success for the class won't come until 2013 when the first outcomes data are available
Published on 11/21/2011
-
Although Targacept and AstraZeneca's TC-5214 failed in its first Phase III trial, history shows that one failed study in depression doesn't mean a program is dead.
Published on 11/21/2011
-
With Phase II data in hand to validate that blocking PCSK9 can lower cholesterol, Regeneron and Sanofi hope to cement their first-mover status by moving into Phase III by mid-2012.
Published on 11/21/2011
-
Many combinations of investigational agents for cancer now are in the clinic, but new approaches are needed to gain speed and fix a surprising roadblock: there are more combinations than patients to test them.
Published on 11/21/2011
-
Emerging Phase II data suggest the next wave of interferon-free HCV regimens offers real promise, and suggest the new standard of care brought about by HCV protease inhibitors is likely to be supplanted fairly quickly.
Published on 11/14/2011
-
Quite a mouthful in HCV Interferon-free HCV data Phase II data presented at this year's AASLD meeting suggest all-oral, interferon-free regimens may be closer to becoming a reality than had been expected. For …
Published on 11/14/2011
-
Quite a mouthful in HCV Interferon-free HCV Trials At least 20 trials are ongoing or planned with at least one all-oral, interferon-free arm. This month, Pharmasset Inc. (NASDAQ:VRUS) announced the start of its …
Published on 11/14/2011
-
Even though it says the regulatory timetable for cabozantinib in metastatic prostate cancer hasn't changed, Exelixis is paying a heavy price for spooking investors with news about disagreements with FDA.
Published on 11/7/2011
-
Medivation is poised to jump into the post-chemotherapy prostate cancer space, but future clinical data will determine how MDV3100 fits in, particularly with J&J's Zytiga.
Published on 11/7/2011
-
Alzheimer's rewind AD pipeline: Antioxidation/anti-aggregation At least eight compounds in clinical development aim to treat Alzheimer's disease (AD) by mitigating beta amyloid toxicity through anti-oxidant or anti-…
Published on 10/24/2011
-
Alzheimer's rewind AD pipeline: APP processing/beta amyloid production At least nine clinical compounds aim to treat Alzheimer's disease (AD) by targeting the proteolytic processing or production of amyloid …
Published on 10/24/2011
-
Alzheimer's rewind AD pipeline: Serotonin modulators At least 11 serotonin receptor modulators are in clinical development to treat Alzheimer's disease (AD). Whether targeting serotonin signaling would have a …
Published on 10/24/2011
-
Saddled by late-stage clinical failures, companies are looking beyond the well-known players in the core mechanism of AD with a next wave of small molecules.
Published on 10/24/2011
-
The next set of Phase III data in Alzheimer's will come next year from therapeutic antibodies against beta amyloid.
Published on 10/24/2011
-
Sprycel dasatinib's broad kinase activity likely explains why it may cause PAH, whereas more selective TKIs such as Gleevec imatinib have been shown to treat the disease.
Published on 10/24/2011
-
Dynavax's perseverance with Heplisav is paying off with positive Phase III data showing superiority to SOC and an upcoming CDC vote that could expand the HBV vaccine's market.
Published on 10/24/2011
-
Waiting for mAbs in AD AD pipeline: Immunotherapies At least 14 immunotherapeutics or vaccines against beta amyloid are in clinical development to treat Alzheimer's disease (AD). Three Phase III antibodies that are …
Published on 10/24/2011